UK Nurses' Union Cuts Teva Sponsorship Over Israeli Military Links
Nurses 4 Palestine, a UK-based group, said Friday that Carmel O'Boyle, chair of the RCN Council, told it that Teva UK has lost its sponsorship of the RCNi Nursing Leadership Summit, scheduled for Oct. 30. O'Boyle communicated the decision in a letter dated Sept. 23, the group said in a statement on Instagram.
"The decision follows sustained campaigning ... demanding that UK healthcare institutions end complicity with corporate actors linked to Israeli apartheid and violations of international law," the group said.
Nurses 4 Palestine worked on the campaign alongside UK Healthcare Petitions to the Royal Colleges, healthcare professionals and union members, all of whom had pressed the RCN over the partnership.
The group said the RCN conceded that further due diligence into the global track record of Teva Pharmaceuticals, "including operations subject to legal sanctions and intense public scrutiny, found the company incompatible with the ethical standards of the nursing profession."
The union also announced a full review aimed at tightening its commercial partnership policy. It directly credited evidence set out in an open letter from the campaigning groups on Sept. 10.
"When frontline workers organise collectively, institutional inertia can be broken, and corporate whitewashing can be stopped," Nurses 4 Palestine said.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
